<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD with MathML3 v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.3" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">research-focus</journal-id>
      <journal-title-group>
        <journal-title>Research Focus International Scientific Journal</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Research Focus</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="epub" publication-format="electronic">2181-3833</issn>
      <publisher>
        <publisher-name>Ilm-fan va innovatsiyalar akademiyasi</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.66073/researchfocus.v2i1.2906</article-id>
      <article-id pub-id-type="other" assigning-authority="relibrary.uz">REL-A-013842</article-id>
      <title-group>
        <article-title xml:lang="en">THE RESULT OF STUDIES OF CLINICAL AND NEUROLOGICAL COMPLICATIONS IN PATIENTS WITH POLYNEUROPATHIES OF THE ETIOLOGY COVID-19</article-title>
        <trans-title-group xml:lang="ru">
          <trans-title>РЕЗУЛЬТАТ ИССЛЕДОВАНИЙ КЛИНИКО-НЕВРОЛОГИЧЕСКИХ ОСЛОЖНЕНИЙ У ПАЦИЕНТОВ С ПОЛИНЕЙРОПАТИЯМИ ЭТИОЛОГИИ COVID-19</trans-title>
        </trans-title-group>
        <trans-title-group xml:lang="uz">
          <trans-title>COVID-19 ETIOLOGIYALI POLINEVROPATIYASI BO‘LGAN BEMORLARDA KLINIK VA NEVROLOGIK ASORATLARNI O‘RGANISH NATIJALARI</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group content-type="author">
        <contrib contrib-type="author">
          <string-name>Isametdinova U.Z.</string-name>
          <aff>Resident of the third year of study, Samarkand State Medical University, Uzbekistan</aff>
        </contrib>
      </contrib-group>
      <pub-date publication-format="electronic" date-type="pub" iso-8601-date="2023-02-05">
        <day>05</day>
        <month>02</month>
        <year>2023</year>
      </pub-date>
      <pub-date date-type="collection">
        <year>2023</year>
      </pub-date>
      <volume>2</volume>
      <issue>1</issue>
      <fpage>542</fpage>
      <lpage>546</lpage>
      <permissions>
        <license xlink:href="https://creativecommons.org/licenses/by/4.0">
          <ali:license_ref>https://creativecommons.org/licenses/by/4.0</ali:license_ref>
          <license-p>This work is licensed under a Creative Commons Attribution 4.0 International License.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="https://relibrary.uz/REL-A-013842/"/>
      <abstract xml:lang="en">
        <p>Most people who fall sick with COVID-19 will experience mild to moderate symptoms and recover without special treatment. However, some will become seriously ill and require medical attention. Coronavirus pandemic 2019-2020 illustrated not only the high aggressiveness of the new infectious agent, moreover its capacity to cause severe cardiovascular complications. During the course of the coronavirus infection, it is possible to develop not only pulmonary, but also other neurological complications. Some symptoms experienced by some people weeks to months after COVID infection suggest the peripheral nervous system, the vast communication network that sends signals between the central nervous system (the brain and spinal cord) and all other parts of the body, is impaired. Objective: To evaluate the clinical and neurological characteristics of patients with polyneuropathies of coronavirus etiology. Methods: The study included 62 patients with polyneuropathies, the main group of 32 patients with polyneuropathies who underwent coronavirus disease and 30 patients with polyneuropathies. The results obtained: At the time of inclusion in the study, patients‘ complaints were dominated by sensory disturbances, signs of numbness, weakness and decreased performance in 97% of patients in the main group and 95% of the comparison group. Conclusion: The conducted clinical and neurological analysis shows that with polyneuropathy there is an increase in neurological symptoms after suffering a coronavirus disease and requires targeted tactics for the introduction and complex treatment of patients.</p>
      </abstract>
      <trans-abstract xml:lang="ru">
        <p>Коронавирусная болезнь (COVID-19) — это инфекционное заболевание, вызываемое вирусом SARS-CoV-2. Большинство людей, которые заболевают COVID-19, будут иметь симптомы легкой или средней степени тяжести и выздоравливают без специального лечения. Однако некоторые серьезно заболеют и потребуют медицинской помощи. Пандемия коронавируса 2019-2020 годов продемонстрировала не только высокую агрессивность нового инфекционного агента, но и его способность вызывать тяжелые сердечно-сосудистые осложнения. В течении коронавирусной инфекции возможно развитие не только легочных, но и других неврологических осложнений. Некоторые симптомы, с которыми сталкиваются некоторые люди через несколько недель или месяцев после заражения COVID, указывают на то, что периферическая нервная система, обширная коммуникационная сеть, которая посылает сигналы между центральной нервной системой (головным и спинным мозгом) и всеми другими частями тела, нарушена. Цель: оценить клинико-неврологическую характеристику пациентов с полиневропатиями коронавирусной этиологии. Методы: в исследование включены 62 пациента с полинейропатиями, основную группу составили 32 пациента с полинейропатиями, перенесшие коронавирусную болезнь, и 30 пациентов с полинейропатиями. Полученные результаты: На момент включения в исследование в жалобах больных преобладали нарушения чувствительности, признаки онемения, слабость и снижение работоспособности у 97% больных основной группы и 95% группы сравнения. Выводы: Проведенный клинико-неврологический анализ показывает, что при полинейропатии наблюдается нарастание неврологической симптоматики после перенесенного коронавирусного заболевания и требует целенаправленной тактики введения и комплексного лечения больных.</p>
      </trans-abstract>
      <trans-abstract xml:lang="uz">
        <p>Koronavirus kasalligi (COVID-19) SARS-CoV-2 virusi keltirib chiqaradigan yuqumli kasallikdir. COVID-19 bilan kasallanganlarning aksariyati yengil va o‘rtacha darajadagi alomatlarni boshdan kechiradi va maxsus davolashsiz tuzalib ketadi. Biroq, ba‘zilari jiddiy kasal bo‘lib, tibbiy yordamga muhtoj bo‘ladi. 2019-2020 yillardagi koronavirus pandemiyasi nafaqat yangi yuqumli agentning yuqori tajovuzkorligini, balki uning yurak-qon tomir tizimiga jiddiy asoratlarni keltirib chiqarish qobiliyatini ham ko‘rsatdi. Koronavirus infektsiyasi davrida nafaqat o‘pka, balki boshqa nevrologik asoratlar ham rivojlanishi mumkin. Ba‘zi odamlarda COVID infektsiyasidan haftalar va oylar o‘tgach sodir bo‘lgan ba‘zi alomatlar periferik asab tizimi, markaziy asab tizimi (miya va orqa miya) va tananing boshqa barcha qismlari o‘rtasida signallarni yuboradigan keng aloqa tarmog‘i buzilganligini ko‘rsatadi. Maqsad: Koronavirus etiologiyasining polinevopatiyasi bo‘lgan bemorlarning klinik va nevrologik xususiyatlarini baholash. Usullari: Tadqiqotga polinevopatiyasi bo‘lgan 62 bemor, koronavirus kasalligi bilan og‘rigan 32 polinevopatiyali bemorning asosiy guruhi va polinevopatiyasi bo‘lgan 30 bemor ishtirok etdi. Natijalar: Tadqiqotga qo‘shilish vaqtida bemorlarning shikoyatlarida asosiy guruhdagi bemorlarning 97 foizida va taqqoslash guruhining 95 foizida hissiy buzilishlar, uyqusizlik, zaiflik va ish faoliyatini pasaytirish belgilari ustunlik qildi. Xulosa: O‘tkazilgan klinik va nevrologik tahlillar shuni ko‘rsatadiki, polineyropatiya bilan koronavirus kasalligi bilan og‘riganidan keyin nevrologik alomatlar kuchayadi va bemorlarni joriy etish va kompleks davolash uchun maqsadli taktika talab qiladi.</p>
      </trans-abstract>
      <kwd-group xml:lang="en">
        <kwd>polyneuropathy</kwd>
        <kwd>neurological symptoms</kwd>
        <kwd>complications</kwd>
        <kwd>COVID-19</kwd>
      </kwd-group>
      <kwd-group xml:lang="ru">
        <kwd>полиневропатия</kwd>
        <kwd>неврологическая симптоматика</kwd>
        <kwd>осложнения</kwd>
        <kwd>COVID-19</kwd>
      </kwd-group>
      <kwd-group xml:lang="uz">
        <kwd>polinevropatiya</kwd>
        <kwd>nevrologik alomatlar</kwd>
        <kwd>asoratlar</kwd>
        <kwd>COVID-19</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <back>
    <ref-list>
      <ref id="r1">
        <label>1</label>
        <mixed-citation>Вознюк И.А., Ильина О.М., Коломенцев С.В Ишемический инсульт как клиническая форма и патогенетическая модель в структуре поражения центральной нервной системы при COVID-19. Вестник восстановительной медицины,- Ne 4 (98). 2020, - C.90-98</mixed-citation>
      </ref>
      <ref id="r2">
        <label>2</label>
        <mixed-citation>Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle region—case series. N Engl J Med. 2020;382(21):2012–2022.</mixed-citation>
      </ref>
      <ref id="r3">
        <label>3</label>
        <mixed-citation>Bocci T, Campiglio L, Zardoni M, et al. Critical illness neuropathy in severe COVID- 19: a case series. Neurol Sci. 2021;42(12):4893-4898.</mixed-citation>
      </ref>
      <ref id="r4">
        <label>4</label>
        <mixed-citation>Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020:382(23):2268-2270. doi: <pub-id pub-id-type="doi">10.1056/NEJMc2008597PubMedGoogle</pub-id> Scholar</mixed-citation>
      </ref>
      <ref id="r5">
        <label>5</label>
        <mixed-citation>Peric S, Stulnig TM. Diabetes and COVID-19: disease-management-people. Wien Klin Wochenschr. 2020;132(13-14):356–361.</mixed-citation>
      </ref>
      <ref id="r6">
        <label>6</label>
        <mixed-citation>Sanyaolu A, Okorie C, Marinkovic A, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med. 2020;2(8):1069–1076.</mixed-citation>
      </ref>
      <ref id="r7">
        <label>7</label>
        <mixed-citation>Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;200950. do:<pub-id pub-id-type="doi">10.1001/jamacar</pub-id> dio.2020.0950ArticlePubMedGoogle Scholar</mixed-citation>
      </ref>
      <ref id="r8">
        <label>8</label>
        <mixed-citation>Treister R, Lodahl M, Lang M, Tworoger SS, Sawilowsky S, Oaklander AL. Initial development and validation of a patient-reported symptom survey for small-fiber polyneuropathy. J Pain. 2017;18(5):556-563.</mixed-citation>
      </ref>
      <ref id="r9">
        <label>9</label>
        <mixed-citation>World Health Organization. Coronavirus (COVID-2019) situation reports. Accessed June 15, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/.</mixed-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <mixed-citation>World Health Organization A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus. 2021. Accessed October 1, 2021. WHO/2019-nCoV/Post_COVID- 19_condition/Clinical_case_definition/2021.1.Google Scholar</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
